Symbols / PEPG $1.82 +5.20% PepGen Inc.

Healthcare • Biotechnology • United States • NMS
PEPG Chart
About

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 125.79M
Enterprise Value -11.88M Income -89.66M Sales —
Book/sh 2.14 Cash/sh 2.15 Dividend Yield —
Payout 0.00% Employees 56 IPO —
P/E — Forward P/E -1.56 PEG —
P/S — P/B 0.85 P/C —
EV/EBITDA 0.13 EV/Sales — Quick Ratio 11.74
Current Ratio 11.94 Debt/Eq 11.53 LT Debt/Eq —
EPS (ttm) -2.12 EPS next Y -1.16 EPS Growth —
Revenue Growth — Earnings 2026-05-14 ROA -36.03%
ROE -67.39% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 69.12M
Shs Float 36.97M Short Float 6.24% Short Ratio 5.33
Short Interest — 52W High 7.80 52W Low 0.88
Beta 2.34 Avg Volume 1.25M Volume 1.89M
Target Price $10.29 Recom Strong_buy Prev Close $1.73
Price $1.82 Change 5.20%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$10.29
Mean price target
2. Current target
$1.82
Latest analyst target
3. DCF / Fair value
$-12.98
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.82
Low
$3.00
High
$20.00
Mean
$10.29

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-01 main Wedbush Outperform → Outperform $5
2026-03-31 main Wedbush Outperform → Outperform $5
2026-02-25 init Oppenheimer — → Outperform $15
2026-02-18 main Guggenheim Buy → Buy $7
2025-11-13 main HC Wainwright & Co. Buy → Buy $20
2025-10-27 main HC Wainwright & Co. Buy → Buy $18
2025-09-30 main Wedbush Outperform → Outperform $8
2025-09-25 main Stifel Buy → Buy $12
2025-09-25 main Wedbush Outperform → Outperform $9
2025-09-25 main HC Wainwright & Co. Buy → Buy $12
2025-09-24 reit Guggenheim Buy → Buy $6
2025-09-09 init Guggenheim — → Buy $6
2025-05-29 main HC Wainwright & Co. Buy → Buy $8
2025-05-09 main HC Wainwright & Co. Buy → Buy $14
2025-02-24 reit HC Wainwright & Co. Buy → Buy $16
2025-01-30 main HC Wainwright & Co. Buy → Buy $16
2024-12-16 down B of A Securities Neutral → Underperform $3
2024-11-18 main B of A Securities Neutral → Neutral $6
2024-11-08 main Wedbush Outperform → Outperform $12
2024-11-08 reit HC Wainwright & Co. Buy → Buy $26
News
RSS: Latest PEPG news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-04 STRECK PAUL Officer — 1,879 $6.23 $11,709
2026-03-04 MCARTHUR JAMES G Chief Executive Officer — 5,275 $6.23 $32,876
2026-03-04 DONNELLY NOEL Chief Financial Officer — 2,084 $6.23 $12,988
2026-02-27 VITTIGLIO JOSEPH D Officer — 30,717 $0.00 $0
2026-02-27 STRECK PAUL Officer — 50,300 $0.00 $0
2026-02-27 MCARTHUR JAMES G Chief Executive Officer — 187,688 $0.00 $0
2026-02-27 DONNELLY NOEL Chief Financial Officer — 76,793 $0.00 $0
2026-02-27 KASRAIAN KASRA PH.D. Chief Technology Officer — 34,557 $0.00 $0
2025-12-08 VITTIGLIO JOSEPH D Officer — 35,000 $0.00 $0
2025-09-30 OXFORD SCIENCES ENTERPRISES PLC Unknown — 200,000 $4.62 $924,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
93.61
-4.22%
97.74
+15.30%
84.77
+24.11%
68.30
Research And Development
71.04
-7.11%
76.48
+12.26%
68.13
+25.98%
54.08
Selling General And Administration
22.57
+6.15%
21.26
+27.77%
16.64
+16.99%
14.22
General And Administrative Expense
22.57
+6.15%
21.26
+27.77%
16.64
+16.99%
14.22
Other Gand A
22.57
+6.15%
21.26
+27.77%
16.64
+16.99%
14.22
Total Expenses
93.61
-4.22%
97.74
+15.30%
84.77
+24.11%
68.30
Operating Income
-93.61
+4.22%
-97.74
-15.30%
-84.77
-24.11%
-68.30
Total Operating Income As Reported
-93.61
+4.22%
-97.74
-15.30%
-84.77
-24.11%
-68.30
EBITDA
-88.47
+4.35%
-92.49
-10.21%
-83.92
-23.76%
-67.81
Normalized EBITDA
-88.47
+4.35%
-92.49
-10.21%
-83.92
-23.76%
-67.81
Reconciled Depreciation
5.14
-2.06%
5.25
+518.00%
0.85
+72.41%
0.49
EBIT
-93.61
+4.22%
-97.74
-15.30%
-84.77
-24.11%
-68.30
Net Income
-89.66
+0.36%
-89.98
-14.44%
-78.63
-13.78%
-69.10
Pretax Income
-89.61
+1.09%
-90.60
-15.33%
-78.55
-20.12%
-65.40
Net Non Operating Interest Income Expense
4.02
-43.76%
7.14
+11.59%
6.40
+129.14%
2.79
Net Interest Income
4.02
-43.76%
7.14
+11.59%
6.40
+129.14%
2.79
Interest Income Non Operating
4.02
-43.76%
7.14
+11.59%
6.40
+129.14%
2.79
Interest Income
4.02
-43.76%
7.14
+11.59%
6.40
+129.14%
2.79
Other Income Expense
-0.01
-1000.00%
-0.00
+99.47%
-0.19
-270.00%
0.11
Other Non Operating Income Expenses
-0.01
-1000.00%
-0.00
+99.47%
-0.19
-270.00%
0.11
Tax Provision
0.05
+107.94%
-0.62
-945.21%
0.07
-98.03%
3.71
Tax Rate For Calcs
0.00
+2900.00%
0.00
-96.67%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-89.66
+0.36%
-89.98
-14.44%
-78.63
-13.78%
-69.10
Net Income From Continuing Operation Net Minority Interest
-89.66
+0.36%
-89.98
-14.44%
-78.63
-13.78%
-69.10
Net Income From Continuing And Discontinued Operation
-89.66
+0.36%
-89.98
-14.44%
-78.63
-13.78%
-69.10
Net Income Continuous Operations
-89.66
+0.36%
-89.98
-14.44%
-78.63
-13.78%
-69.10
Normalized Income
-89.66
+0.36%
-89.98
-14.44%
-78.63
-13.78%
-69.10
Net Income Common Stockholders
-89.66
+0.36%
-89.98
-14.44%
-78.63
-13.78%
-69.10
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
-2.12
+25.61%
-2.85
+13.64%
-3.30
-13.24%
-2.91
Basic EPS
-2.12
+25.61%
-2.85
+13.64%
-3.30
-13.24%
-2.91
Basic Average Shares
42.22
+33.68%
31.58
+32.72%
23.80
+0.35%
23.71
Diluted Average Shares
42.22
+33.68%
31.58
+32.72%
23.80
+0.35%
23.71
Diluted NI Availto Com Stockholders
-89.66
+0.36%
-89.98
-14.44%
-78.63
-13.78%
-69.10
Line Item Trend 2023-12-31
Total Assets
143.05
Current Assets
112.68
Cash Cash Equivalents And Short Term Investments
110.41
Cash And Cash Equivalents
80.77
Other Short Term Investments
29.63
Receivables
—
Other Receivables
—
Prepaid Assets
—
Other Current Assets
2.27
Total Non Current Assets
30.37
Net PPE
28.38
Gross PPE
29.96
Accumulated Depreciation
-1.57
Properties
0.00
Machinery Furniture Equipment
1.45
Construction In Progress
0.07
Other Properties
28.44
Leases
23.62
Other Non Current Assets
1.99
Total Liabilities Net Minority Interest
34.63
Current Liabilities
17.53
Payables And Accrued Expenses
12.16
Payables
1.00
Accounts Payable
1.00
Current Accrued Expenses
11.15
Pensionand Other Post Retirement Benefit Plans Current
2.37
Total Tax Payable
0.00
Current Debt And Capital Lease Obligation
3.00
Current Capital Lease Obligation
3.00
Total Non Current Liabilities Net Minority Interest
17.10
Long Term Debt And Capital Lease Obligation
17.10
Long Term Capital Lease Obligation
17.10
Stockholders Equity
108.42
Common Stock Equity
108.42
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
23.82
Ordinary Shares Number
23.82
Treasury Shares Number
0.00
Additional Paid In Capital
289.87
Retained Earnings
-181.48
Gains Losses Not Affecting Retained Earnings
0.03
Other Equity Adjustments
0.03
Total Equity Gross Minority Interest
108.42
Total Capitalization
108.42
Working Capital
95.15
Invested Capital
108.42
Total Debt
20.10
Capital Lease Obligations
20.10
Net Tangible Assets
108.42
Tangible Book Value
108.42
Derivative Product Liabilities
—
Preferred Stock Equity
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-81.64
+0.89%
-82.37
-19.38%
-69.00
-16.42%
-59.27
Cash Flow From Continuing Operating Activities
-81.64
+0.89%
-82.37
-19.38%
-69.00
-16.42%
-59.27
Net Income From Continuing Operations
-89.66
+0.36%
-89.98
-14.44%
-78.63
-13.78%
-69.10
Depreciation Amortization Depletion
5.14
-2.06%
5.25
+518.00%
0.85
+72.41%
0.49
Depreciation
1.40
-7.18%
1.50
+27.11%
1.18
+140.16%
0.49
Amortization Cash Flow
3.75
+0.00%
3.75
+1222.16%
-0.33
0.00
Depreciation And Amortization
5.14
-2.06%
5.25
+518.00%
0.85
+72.41%
0.49
Amortization Of Intangibles
3.75
+0.00%
3.75
+1222.16%
-0.33
0.00
Other Non Cash Items
—
0.07
—
0.13
Stock Based Compensation
10.61
-7.40%
11.46
+62.56%
7.05
+47.97%
4.76
Asset Impairment Charge
0.70
0.00
—
—
Operating Gains Losses
—
—
—
0.08
Gain Loss On Investment Securities
—
—
—
-0.06
Gain Loss On Sale Of PPE
—
—
0.00
-100.00%
0.13
Change In Working Capital
-6.22
-18.62%
-5.25
-368.89%
1.95
-56.71%
4.51
Change In Receivables
—
—
0.03
-99.38%
4.18
Change In Prepaid Assets
1.07
+182.55%
-1.30
-163.03%
2.06
+215.70%
-1.78
Change In Payables And Accrued Expense
-4.20
-346.65%
-0.94
-189.36%
1.05
-74.47%
4.12
Change In Accrued Expense
-3.27
-96.51%
-1.66
-216.95%
1.42
-74.29%
5.53
Change In Payable
-0.94
-229.50%
0.72
+295.66%
-0.37
+73.77%
-1.41
Change In Account Payable
-0.94
-229.50%
0.72
+295.66%
-0.37
+73.77%
-1.41
Change In Other Current Assets
—
—
—
0.00
Change In Other Current Liabilities
-3.09
-3.00%
-3.00
-157.63%
-1.17
+42.16%
-2.02
Investing Cash Flow
-15.23
+59.55%
-37.67
-17.70%
-32.00
-752.28%
-3.75
Cash Flow From Continuing Investing Activities
-15.23
+59.55%
-37.67
-17.70%
-32.00
-752.28%
-3.75
Net PPE Purchase And Sale
-0.26
+46.88%
-0.50
+80.88%
-2.60
+30.79%
-3.75
Purchase Of PPE
-0.26
+46.88%
-0.50
+80.88%
-2.60
+30.79%
-3.75
Capital Expenditure
-0.26
+46.88%
-0.50
+80.88%
-2.60
+30.79%
-3.75
Net Investment Purchase And Sale
-14.97
+59.72%
-37.17
-26.41%
-29.40
0.00
Purchase Of Investment
-93.97
+35.27%
-145.17
-393.71%
-29.40
0.00
Sale Of Investment
79.00
-26.85%
108.00
0.00
—
Financing Cash Flow
107.98
+21.67%
88.75
+47057.14%
-0.19
-100.17%
112.19
Cash Flow From Continuing Financing Activities
107.98
+21.67%
88.75
+47057.14%
-0.19
-100.17%
112.19
Net Common Stock Issuance
108.10
+24.57%
86.78
0.00
-100.00%
114.27
Proceeds From Stock Option Exercised
0.29
-88.24%
2.48
+881.03%
0.25
-59.39%
0.62
Net Other Financing Charges
-0.41
+19.18%
-0.51
-15.61%
-0.44
+83.61%
-2.70
Changes In Cash
11.11
+135.50%
-31.29
+69.08%
-101.19
-305.78%
49.17
Effect Of Exchange Rate Changes
-0.02
+74.19%
-0.06
-121.68%
0.29
+190.51%
-0.32
Beginning Cash Position
50.97
-38.09%
82.32
-55.07%
183.22
+36.36%
134.37
End Cash Position
62.06
+21.76%
50.97
-38.09%
82.32
-55.07%
183.22
Free Cash Flow
-81.90
+1.17%
-82.87
-15.75%
-71.60
-13.61%
-63.02
Income Tax Paid Supplemental Data
0.08
+15.49%
0.07
-97.37%
2.70
0.00
Amortization Of Securities
-2.21
+43.64%
-3.92
-1684.09%
-0.22
0.00
Common Stock Issuance
108.10
+24.57%
86.78
0.00
-100.00%
114.27
Issuance Of Capital Stock
108.10
+24.57%
86.78
0.00
-100.00%
114.27
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category